Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements

Esperion Therapeutics Inc (NASDAQ:ESPR) is among the best NASDAQ penny stocks to buy according to analysts. On February 17, Esperion Therapeutics Inc (NASDAQ:ESPR) struck a deal with Alkem Laboratories regarding the sale of rival generic drugs. Specifically, Esperion got Alkem to agree that it would not sell generic versions of Esperion’s drugs NEXLETOL and NEXLIZET in the US market before April 19, 2040.

This deal with Alkem is part of Esperion’s ongoing campaign to delay generic competition for NEXLETOL and NEXLIZET. On January 11, Esperion announced that it had reached a deal restricting Dr. Reddy’s Laboratories and at least three other companies from introducing generic versions of its drugs before April 2040.

These generic drug agreements come at a time when Esperion has outlined its Vision 2040 plan. In this plan, Esperion is focused on becoming a leader in cardiometabolic disease therapies. Toward this end, the company aims to have at least five products on the market, build a robust pipeline that addresses various unmet medical needs, and forge strong international partnerships.

In 2025, Esperion reported preliminary U.S. net product sales of $156–$160 million, a 35%–38% increase over 2024, according to results released January 11.

Esperion Therapeutics Inc (NASDAQ:ESPR) is a biopharmaceutical company focused on developing medicines for cardiometabolic diseases and other rare conditions. The company has two drug products on the market, which are approved in more than 40 countries. The company was founded in 1998 and is headquartered in Ann Arbor, Michigan.

While we acknowledge the potential of ESPR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 11 Best Italian Stocks to Buy in 2026.

Disclosure: None.  Follow Insider Monkey on Google News.